Circulating DNA and Next-Generation Sequencing

  • Susanna Cooke
  • Peter Campbell
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 195)


Personalising cancer medicine depends upon the implementation of personalised diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this. As the range of drugs and other therapies for cancer continues to increase, there is an increasingly urgent need for sensitive and specific measures of disease burden to guide treatment regimens. The ability to quantify disease burden with high accuracy and sensitivity in patients with cancer would open many potential routes to personalising therapeutic choices. For example, the intensity of therapy could be guided by the amount of disease at diagnosis; monitoring the response of patients to drugs could allow extension of the period of treatment in responders or early changeover of therapy in nonresponders; and early prediction of recurrence could allow salvage therapy to be instituted before complications of relapse develop. The detection of tumour-specific rearrangements in DNA free in the serum or plasma may provide a substantial advance in the accuracy of monitoring disease burden in patients with solid tumours.


Minimal Residual Disease Tumour Genome Somatic Rearrangement Reference Human Genome Sequence Bisulphite Conversion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Am Soc Hematol Educ Program 2007:376CrossRefGoogle Scholar
  2. 2.
    Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l′homme. CR Acad Sci Paris 142:241Google Scholar
  3. 3.
    Steinman CR (1975) Free DNA in serum and plasma from normal adults. J Clin Invest 56:512PubMedCrossRefGoogle Scholar
  4. 4.
    Stroun M, Lyautey J, Lederrey C et al (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clinica chimica acta; J Clin Chem 313:139CrossRefGoogle Scholar
  5. 5.
    Choi JJ, Reich CF 3rd, Pisetsky DS (2005) The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 115:55PubMedCrossRefGoogle Scholar
  6. 6.
    Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659PubMedGoogle Scholar
  7. 7.
    Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102:16368PubMedCrossRefGoogle Scholar
  8. 8.
    Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646PubMedGoogle Scholar
  9. 9.
    Fournie GJ, Courtin JP, Laval F et al (1995) Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91:221PubMedCrossRefGoogle Scholar
  10. 10.
    Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985PubMedCrossRefGoogle Scholar
  11. 11.
    Sorenson GD, Pribish DM, Valone FH et al (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3:67Google Scholar
  12. 12.
    Leary RJ, Kinde I, Diehl F et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2:20ra14PubMedCrossRefGoogle Scholar
  13. 13.
    Esteller M, Sanchez-Cespedes M, Rosell R et al (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67PubMedGoogle Scholar
  14. 14.
    Wong IH, Lo YM, Zhang J et al (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71PubMedGoogle Scholar
  15. 15.
    Grutzmann R, Molnar B, Pilarsky C et al (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PloS One 3:e3759PubMedCrossRefGoogle Scholar
  16. 16.
    Margulies M, Egholm M, Altman WE et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376Google Scholar
  17. 17.
    Bentley DR, Balasubramanian S, Swerdlow HP et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53PubMedCrossRefGoogle Scholar
  18. 18.
    McKernan KJ, Peckham HE, Costa GL et al (2009) Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 19:1527PubMedCrossRefGoogle Scholar
  19. 19.
    Campbell PJ, Stephens PJ, Pleasance ED et al (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40:722PubMedCrossRefGoogle Scholar
  20. 20.
    McBrid DJ, Orpana AK, Sotiriou C et al (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosom Cancer 49:1062CrossRefGoogle Scholar
  21. 21.
    Umetani N, Giuliano AE, Hiramatsu SH et al (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270PubMedCrossRefGoogle Scholar
  22. 22.
    Wang M, Block TM, Steel L et al (2004) Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 50:211PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Wellcome Trust Sanger InstituteCambridgeUK

Personalised recommendations